Medxy AI

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial

By MedXY 06/28/2026

The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten as a superior first-line therapy.

Cardiology news

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

By MedXY 06/28/2026

The FOREST-HCM long-term study confirms aficamten's efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.

Cardiology news

Long-Term Success of Combined Myectomy and Secondary Mitral Chordal Cutting in Obstructive Hypertrophic Cardiomyopathy

By MedXY 06/28/2026

This study demonstrates that septal myectomy combined with cutting of secondary mitral valve chordae delivers excellent long-term survival and symptom relief in obstructive hypertrophic cardiomyopathy patients unresponsive to medical therapy.

Hematology-Oncology news Oncology

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

By MedXY 06/28/2026

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring showing near-universal clearance post-therapy.

Gastroenterology Internal Medicine news

Evaluating Telehealth Stepped Alcohol Treatment to Reduce Alcohol Use in Chronic Liver Disease: Insights from a 2026 Randomized Controlled Trial

By MedXY 06/27/2026

A 2026 RCT assessed telehealth stepped alcohol treatment in chronic liver disease patients, finding significant reductions in weekly alcohol consumption but no difference in achieving moderate drinking levels compared to usual care.

Gastroenterology news Oncology

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY 06/27/2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and improving antitumor immunity.

Gastroenterology news

BIRC3 Gene Variants Disrupt RIPK1 Signaling, Driving Monogenic Crohn’s Disease: New Insights and Therapeutic Avenues

By MedXY 06/27/2026

Rare variants in the BIRC3 gene cause defective regulation of RIPK1 signaling, leading to increased intestinal epithelial cell death and monogenic Crohn's disease. Targeting RIPK1 offers a promising therapeutic strategy.

Neurology news

Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 Trial

By MedXY 06/27/2026

Secondary analysis of the TEMPO-2 trial reveals that successful recanalization significantly improves 90-day functional outcomes in minor ischemic stroke patients with proven occlusion, with tenecteplase markedly enhancing recanalization rates compared to standard care.

Neurology news

Distinct Early Cerebral Edema Subtypes as Predictors of Outcome in Cerebral Venous Thrombosis: Insights from the CLOT-VENUS Registry

By MedXY 06/27/2026

This study identifies global and cytotoxic cerebral edema subtypes in cerebral venous thrombosis as key determinants of poor functional outcomes and mortality, providing new avenues for early risk stratification and targeted adjunctive therapies.

Clinical Updates Neurology news

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia: An Integrative Review

By MedXY 06/27/2026

This review synthesizes current evidence on CSF TMEM106B levels in FTLD, highlighting their associations with disease severity, genetic variants, brain atrophy, and clinical progression, emphasizing TMEM106B's potential as a biomarker and mechanistic insight into neurodegeneration.

Clinical Updates Diabetes & Endocrinology news Pediatrics

Evolving Paradigms in Pediatric Hyperthyroidism: A Two-Decade Review of Management and Outcomes

By MedXY 06/27/2026

This review synthesizes 20 years of data on pediatric hyperthyroidism, highlighting shifts toward prolonged antithyroid drug therapy, reduced definitive treatments, and rising relapse rates, underscoring the need for individualized long-term management.

Diabetes & Endocrinology news

Metabolic State-Dependent Mechanisms of Liraglutide in Enhancing Insulin Secretion and Glycemic Control

By MedXY 06/27/2026

Liraglutide’s efficacy in type 2 diabetes varies with metabolic state, engaging brain-mediated insulin secretion in healthy individuals, direct islet action in glucose intolerance, and insulin-independent pathways in advanced disease stages, guiding tailored therapeutic strategies.

Diabetes & Endocrinology news

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

By MedXY 06/27/2026

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in those with preserved β-cell function.

Diabetes & Endocrinology news

Proteomic Markers Predicting Progression from Impaired Fasting Glucose to Diabetes: Insights from the ARIC Study

By MedXY 06/27/2026

This study identifies six plasma proteins associated with 3-year progression from impaired fasting glucose to diabetes, enhancing risk prediction and offering new mechanistic insights.

Clinical Updates Internal Medicine news Public Health

Whole-Population Trends in Obesity and Inequality in England, 2019-2025: Insights from a Cohort of 54 Million Adults

By MedXY 06/27/2026

Analyzing 54 million adults in England reveals rising obesity rates from 2019-2025, disproportionately affecting socioeconomically deprived, ethnic minority, and younger adult groups, with widening inequalities intensified during the COVID-19 pandemic.

Cardiology news

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank

By MedXY 06/27/2026

Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment and prevention strategies.

Clinical Updates news

Laminopathies: Natural History and Risk Prediction of Heart Failure

By MedXY 06/26/2026

This review synthesizes recent advances in understanding the natural history of LMNA-related cardiomyopathies and introduces the first validated prediction model for severe heart failure events, enhancing early risk stratification and management.

Cardiology news

Unveiling the Burden of Valvular Heart Disease Among Older Americans: Insights from the PREVUE-VALVE Study

By MedXY 06/26/2026

The PREVUE-VALVE study reveals a significant prevalence of moderate or greater valvular heart disease among U.S. adults aged 65-85, highlighting substantial public health implications and the value of decentralized echocardiographic screening.

Cardiology Clinical Updates news

Association of Common Ancestry-Enriched Variants With Cardiomyopathy and Arrhythmias: Insights From Genetic Studies in Individuals of African Ancestry

By MedXY 06/26/2026

Genetic variants enriched in individuals of African ancestry confer increased risk of cardiomyopathy and arrhythmias, with cardiovascular risk factors amplifying this risk. Large biobank studies enable reclassification of key variants and highlight the need for ancestry-specific genetic risk assessment.

news OB/GYN & Women’s Health Oncology

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

By MedXY 06/26/2026

This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of secondary hematologic malignancies.